期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 31, 期 6, 页码 531-548出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543784.2022.1986002
关键词
Atezolizumab; breast cancer; checkpoint inhibitors; durvalumab; immunotherapy; small-molecule inhibitors; PARP inhibitors; pembrolizumab; triple negative breast cancer
资金
- University of Chicago
- NIH [1F32CA265232-01, 5T32CA009566-33]
Breast cancer has traditionally been considered immunogenically 'cold,' but recent approvals of immune checkpoint inhibitors for advanced triple-negative breast cancer show promise. Ongoing studies are investigating novel combination strategies to enhance response to immunotherapy and overcome resistance. Biomarkers are needed to predict immunotherapy benefits in the curative setting.
Introduction Breast cancer has traditionally been viewed as immunogenically 'cold,' but two immune checkpoint inhibitors have been approved in combination with chemotherapy for PD-L1 positive advanced triple-negative breast cancer (TNBC), and pembrolizumab was also recently approved for early stage TNBC. As the landscape is rapidly evolving, a comprehensive review of checkpoint inhibitors in breast cancer is needed to aid clinicians in selecting appropriate candidates for therapy, and to highlight ongoing promising studies in this area and topics in need of further investigation. Area covered This review summarizes the latest evidence from completed and ongoing trials of immune checkpoint inhibitors. Ongoing studies were identified using a search of ClinicalTrials.gov with the term 'breast cancer' along with specific checkpoint inhibitor agents. Expert opinion A number of novel combination strategies are under investigation to enhance response and overcome resistance to immunotherapy, with promising preliminary data from checkpoint inhibitors targeting TIGIT, combinations with small molecule inhibitors such as lenvatinib, and injectable agents directly influencing the immune microenvironment. As immunotherapy enters into the curative setting, biomarkers predictive of immunotherapy benefit are needed, as PD-L1 status has not been a helpful discriminator in completed trials in early-stage breast cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据